Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXM01 · 3 trials · 3 indications
AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.
Number of dose-limiting toxicities and maximum tolerated dose
| Arm | Type | Description |
|---|---|---|
| VXM01 | EXPERIMENTAL | VXM01 10E6 or 10E7 CFU |
| Placebo | PLACEBO_COMPARATOR | Placebo control |
| Name | Type | Description |
|---|---|---|
| VXM01 | DRUG | Oral immunotherapy targeting VEGFR2 |
| Placebo | BIOLOGICAL | Drink solution |
Inclusion Criteria: 1. Written informed consent, signed and dated 2. Histologically diagnosed intracranial supratentorial malignant glioma (contrast-enhancing anaplastic astrocytoma WHO Grade III or glioblastoma WHO Grade IV). 3. Male or female patients who must be post-menopausal for at least 2 ye...
VXM01 is an investigational small molecule being studied for the treatment of glioblastoma, colorectal cancer, and stage IV pancreatic cancer. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
VXM01 is being developed by OSR Holdings, Inc., a company listed on the stock exchange under the ticker symbol OSRH. The drug is in Phase 1 clinical trials for multiple oncology indications.
VXM01 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. Clinical trials for the drug have been completed, and it is not currently in active trials.
VXM01 has been studied in three completed Phase 1 clinical trials: NCT01486329 for stage IV pancreatic cancer, NCT02718430 for metastatic colorectal cancer, and NCT02718443 for recurrent glioblastoma. These trials were conducted in Germany.
VXM01 is a small molecule therapeutic. Its specific molecular target has not been disclosed in available information, so its mechanism of action is not fully characterized in public data.
No alternative names for VXM01 have been identified in available information. The drug is known only by its code name VXM01 in clinical trial registries and public data.